Does the media prefer ADMA or ANIP?

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 3 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.71 beat ADMA Biologics' score of 0.54 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ANIP or ANVS?

In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Annovis Bio. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 2 mentions for Annovis Bio. ANI Pharmaceuticals' average media sentiment score of 0.71 beat Annovis Bio's score of 0.51 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Annovis Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, LQDA or ANIP?

ANI Pharmaceuticals has higher revenue and earnings than Liquidia. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 37.06 -$68.92M $1.37 47.85 ANI Pharmaceuticals $883.37M 1.85 $78.34M $4.64 15.32

Does the media prefer LQDA or ANIP?

In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Liquidia. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 6 mentions for Liquidia. Liquidia's average media sentiment score of 1.10 beat ANI Pharmaceuticals' score of 0.71 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer AMRX or ANIP?

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 8 mentions for Amneal Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.71 beat Amneal Pharmaceuticals' score of 0.26 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ANIP or DFTX?

In the previous week, Definium Therapeutics had 15 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 26 mentions for Definium Therapeutics and 11 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.71 beat Definium Therapeutics' score of 0.18 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Definium Therapeutics 3 Very Positive mention(s) 10 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Neutral

ANI Pharmaceuticals (ANIP) Competitors

$71.08 +0.89 (+1.27%)

As of 11:19 AM Eastern

Compare

ANIP vs. ADMA, ANVS, LQDA, AMRX, and DFTX

Should you buy ANI Pharmaceuticals stock or one of its competitors? ANI Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), Annovis Bio (ANVS), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

ADMA Biologics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

ADMA Biologics presently has a consensus price target of $18.67, suggesting a potential upside of 105.15%. ANI Pharmaceuticals has a consensus price target of $105.57, suggesting a potential upside of 48.52%. Given ADMA Biologics' higher probable upside, research analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

ADMA Biologics has a net margin of 32.98% compared to ANI Pharmaceuticals' net margin of 11.07%. ADMA Biologics' return on equity of 40.17% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 3 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.71 beat ADMA Biologics' score of 0.54 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$512.28M	3.98	$146.93M	$0.70	13.00
ANI Pharmaceuticals	$883.37M	1.85	$78.34M	$4.64	15.32

Summary

ANI Pharmaceuticals beats ADMA Biologics on 9 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

ANI Pharmaceuticals (NASDAQ:ANIP) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

ANI Pharmaceuticals presently has a consensus target price of $105.57, indicating a potential upside of 48.52%. Annovis Bio has a consensus target price of $12.00, indicating a potential upside of 954.48%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Annovis Bio. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 2 mentions for Annovis Bio. ANI Pharmaceuticals' average media sentiment score of 0.71 beat Annovis Bio's score of 0.51 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Annovis Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has a net margin of 11.07% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Annovis Bio	N/A	-685.98%	-258.77%

ANI Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.85	$78.34M	$4.64	15.32
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ANI Pharmaceuticals beats Annovis Bio on 12 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Liquidia has a net margin of 30.74% compared to ANI Pharmaceuticals' net margin of 11.07%. Liquidia's return on equity of 149.65% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

ANI Pharmaceuticals has higher revenue and earnings than Liquidia. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	37.06	-$68.92M	$1.37	47.85
ANI Pharmaceuticals	$883.37M	1.85	$78.34M	$4.64	15.32

Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Liquidia presently has a consensus price target of $98.08, indicating a potential upside of 49.62%. ANI Pharmaceuticals has a consensus price target of $105.57, indicating a potential upside of 48.52%. Given Liquidia's higher probable upside, analysts plainly believe Liquidia is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Liquidia. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 6 mentions for Liquidia. Liquidia's average media sentiment score of 1.10 beat ANI Pharmaceuticals' score of 0.71 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Liquidia beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Amneal Pharmaceuticals currently has a consensus target price of $19.57, suggesting a potential upside of 14.91%. ANI Pharmaceuticals has a consensus target price of $105.57, suggesting a potential upside of 48.52%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 8 mentions for Amneal Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.71 beat Amneal Pharmaceuticals' score of 0.26 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

ANI Pharmaceuticals has lower revenue, but higher earnings than Amneal Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.80	$72.06M	$0.49	34.76
ANI Pharmaceuticals	$883.37M	1.85	$78.34M	$4.64	15.32

ANI Pharmaceuticals has a net margin of 11.07% compared to Amneal Pharmaceuticals' net margin of 5.05%. ANI Pharmaceuticals' return on equity of 27.37% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Summary

ANI Pharmaceuticals beats Amneal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Definium Therapeutics?

ANI Pharmaceuticals (NASDAQ:ANIP) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Definium Therapeutics had 15 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 26 mentions for Definium Therapeutics and 11 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.71 beat Definium Therapeutics' score of 0.18 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Definium Therapeutics	3 Very Positive mention(s)	10 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Neutral

ANI Pharmaceuticals has a net margin of 11.07% compared to Definium Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Definium Therapeutics	N/A	-84.01%	-63.66%

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.85	$78.34M	$4.64	15.32
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

ANI Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

ANI Pharmaceuticals currently has a consensus price target of $105.57, suggesting a potential upside of 48.52%. Definium Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 55.82%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

ANI Pharmaceuticals beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.63B	$12.52B	$7.20B	$12.67B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	15.33	797.25	275.02	25.43
Price / Sales	1.85	756.92	638.08	88.25
Price / Cash	7.07	14.86	28.42	34.96
Price / Book	2.96	10.42	10.32	6.23
Net Income	$78.34M	$2.84B	$3.50B	$358.31M
7 Day Performance	-0.21%	-3.55%	-2.41%	-1.59%
1 Month Performance	-7.13%	0.79%	0.22%	-2.89%
1 Year Performance	-27.25%	3.89%	24.17%	8.22%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	4.0463 of 5 stars	$71.08 +1.3%	$105.57 +48.5%	-28.2%	$1.63B	$883.37M	15.33	970
ADMA ADMA Biologics	3.2143 of 5 stars	$9.62 flat	$18.67 +94.0%	-42.7%	$2.15B	$510.17M	13.74	530
ANVS Annovis Bio	2.2621 of 5 stars	$1.38 -0.5%	$12.00 +768.0%	-54.8%	$59.22M	N/A	N/A	3	Analyst Downgrade
LQDA Liquidia	3.8256 of 5 stars	$68.66 flat	$98.08 +42.9%	+156.8%	$6.15B	$158.32M	50.12	50	Analyst Downgrade
AMRX Amneal Pharmaceuticals	3.9414 of 5 stars	$17.44 flat	$19.00 +8.9%	+70.1%	$5.57B	$3.02B	35.59	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, LQDA, AMRX, and DFTX

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Liquidia?

Summary

How does ANI Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does ANI Pharmaceuticals compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, LQDA, AMRX, and DFTX

How does ANI Pharmaceuticals compare to ADMA Biologics?

Which has more risk & volatility, ADMA or ANIP?

Do analysts recommend ADMA or ANIP?

Is ADMA or ANIP more profitable?

Does the media prefer ADMA or ANIP?

Do insiders and institutionals hold more shares of ADMA or ANIP?

Which has preferable valuation & earnings, ADMA or ANIP?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Do analysts recommend ANIP or ANVS?

Does the media refer more to ANIP or ANVS?

Is ANIP or ANVS more profitable?

Which has more risk and volatility, ANIP or ANVS?

Which has preferable earnings & valuation, ANIP or ANVS?

Do institutionals and insiders believe in ANIP or ANVS?

Summary

How does ANI Pharmaceuticals compare to Liquidia?

Is LQDA or ANIP more profitable?

Which has better earnings & valuation, LQDA or ANIP?

Which has more volatility & risk, LQDA or ANIP?

Do insiders and institutionals believe in LQDA or ANIP?

Do analysts rate LQDA or ANIP?

Does the media prefer LQDA or ANIP?

Summary

How does ANI Pharmaceuticals compare to Amneal Pharmaceuticals?

Do analysts prefer AMRX or ANIP?

Does the media prefer AMRX or ANIP?

Which has preferable earnings and valuation, AMRX or ANIP?

Is AMRX or ANIP more profitable?

Do insiders and institutionals hold more shares of AMRX or ANIP?

Which has more volatility and risk, AMRX or ANIP?

Summary

How does ANI Pharmaceuticals compare to Definium Therapeutics?

Does the media refer more to ANIP or DFTX?

Is ANIP or DFTX more profitable?

Do insiders & institutionals have more ownership in ANIP or DFTX?

Which has preferable valuation & earnings, ANIP or DFTX?

Which has more risk and volatility, ANIP or DFTX?

Do analysts recommend ANIP or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools